AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03683628
Drug: No PB-MNC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
Trial: NCT01193153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monthly by i.m. injection for 15 months
Trial: NCT03777761
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for tucatinib
Trial: NCT00172211
Drug: Physioneal
RxNorm normalized name: Physioneal 40 with 1.36% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01314001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch
Trial: NCT00004936
Drug: iodinated contrast dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02748772
Drug: Pure chemotherapy（Xelox）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
Trial: NCT02340949
Drug: 5-Fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
Trial: NCT02340949
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Trial: NCT00106314
Drug: Dehydroepiandrosterone [DHEA]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03573323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02855268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
Trial: NCT00673582
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/day rosuvastatin
Trial: NCT00673582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 10 mg a day for 96 weeks
Trial: NCT02602522
Drug: Shandong Danshen-Jiang-Fu Granule
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
Trial: NCT02602522
Drug: Sichuan Danshen-Jiang-Fu Granule
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
Trial: NCT00261053
Drug: i.v. recombinant human C1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04364269
Drug: VIT-2763 once a day (QD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Trial: NCT04364269
Drug: VIT-2763 twice a day (BID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Trial: NCT04364269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive hard capsules of Placebo, twice a day.
Trial: NCT03743246
Drug: JCAR017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JCAR017
Trial: NCT03743246
Drug: Lymphodepleting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting
Trial: NCT03743246
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT00979056
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Tablet, Oral Use
Trial: NCT01490580
Drug: atropine + atracurium + sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
Trial: NCT00056979
Drug: CAMPATH-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00972504
Drug: GSK835726 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK835726 10mg tablet
Trial: NCT00972504
Drug: GSK1004723 1000mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1004723 1000mcg nasal spray solution
Trial: NCT00972504
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match actives
Trial: NCT01300312
Drug: Eperisone hydrochloride and Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
Trial: NCT03259087
Drug: MK-3866
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
Trial: NCT01849562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01782885
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
Trial: NCT02028533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02304523
Drug: CDFR0612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Trial: NCT02304523
Drug: CDFR0613
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Trial: NCT02304523
Drug: Coolprep Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Trial: NCT03498170
Drug: BCT197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of BCT197
Trial: NCT02114463
Drug: flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
Trial: NCT00269880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
Trial: NCT00269880
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
Trial: NCT00861458
Drug: Pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 750 mg PF-00868554 as a solution and tablets.
Trial: NCT01802632
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
Trial: NCT01983306
Drug: SP-333 1 mg
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01983306
Drug: SP-333 3 mg
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01983306
Drug: SP-333 6 mg
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01983306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04209049
Drug: NNC0174-0833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single subcutaneous (s.c., under the skin) dose of 0.6 mg NNC0174-0833.
Trial: NCT00637234
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
Trial: NCT00637234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 300 mg tablets, up to 600 mg three times daily
Trial: NCT05561036
Drug: Liposome doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
Trial: NCT02416739
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
Trial: NCT00279916
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily.
Trial: NCT01141322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
Trial: NCT01444235
Drug: Custodiol-N
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
Trial: NCT01444235
Drug: Custodiol
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
Trial: NCT00633360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily by mouth
Trial: NCT01964287
Drug: GEMBRAX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01964287
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02517307
Drug: Intralipid/Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
Trial: NCT02517307
Drug: Glycerol/Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
Trial: NCT00650767
Drug: ARRY-438162, MEK inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT00650767
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04346004
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery.
Trial: NCT01235507
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: stable dose as prescribed
Trial: NCT01681290
Drug: CBX129801
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03451435
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
Trial: NCT00432185
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% PEP005 Gel
Trial: NCT00926185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT02770248
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo for masking purposes
Trial: NCT03893032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral-administration placebo tablet
Trial: NCT03384940
Drug: DS-8201a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
Trial: NCT01668849
Drug: Lortab, Fentanyl patch, mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
Trial: NCT00002675
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00704366
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, tablet, once daily, dose will be variable
Trial: NCT00638690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four tablets once daily until disease progression
Trial: NCT00043082
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous q 4 weeks
Trial: NCT02207075
Drug: [C11]PK-1195 PET scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET scan with tracer \[C11\]PK-1195
Trial: NCT03778580
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03659201
Drug: Neosil complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, during 24 weeks.
Trial: NCT03659201
Drug: Pantogar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, placebo for 12 weeks and pantogar for 12 weeks.
Trial: NCT00961636
Drug: Placebo to ERN/LRPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
Trial: NCT01979913
Drug: Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02160106
Drug: TEW-7197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Trial: NCT01768676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03958513
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
Trial: NCT02283840
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00643968
Drug: EFV+TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00643968
Drug: EFV+3TC+TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04567667
Drug: Kinevac®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03812783
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Trial: NCT03812783
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
Trial: NCT03072264
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
Trial: NCT02722200
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
Trial: NCT00555880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00799266
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous infusion
Trial: NCT00799266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00154440
Drug: proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00154440
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02830152
Drug: Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
Trial: NCT04178109
Drug: Dexketoprofen/tramadol (27mg/75mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
Trial: NCT00031473
Drug: Virazole (Ribavirin) Inhalation Solution
RxNorm normalized name: Virazole Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05089643
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine tablets 1000 mg/m2, twice a day, within 30min after meals, were taken orally for 2 consecutive weeks and stopped for 1 week, i.e., 3 weeks (21 days) as a treatment cycle until disease progression or adverse reactions became intolerable.
Trial: NCT01276639
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral BID, Continuous treatment for 52 Weeks
Trial: NCT01276639
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral BID, Continuous treatment for 52 Weeks
Trial: NCT01276639
Drug: Placebo/CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Trial: NCT01276639
Drug: Placebo/CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Trial: NCT01025843
Drug: MK-5478
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
Trial: NCT01025843
Drug: Comparator: Pbo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03967886
Drug: YYD601 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should take drugs an hour before breakfast.
Trial: NCT00174317
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02297386
Drug: [18F] DIHYDRO-TESTOSTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03639324
Drug: Dose combination 1-3
RxNorm normalized name: Habitrol Combination Kit Steps 1-3 Transdermal System (56)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID of idelalisib + 200 mg QD of venetoclax
Trial: NCT03639324
Drug: Sub-Trial: Dose combination 2-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BID of idelalisib + 100 mg QD of venetoclax
Trial: NCT03639324
Drug: Sub-Trial: Dose combination 2-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg BID of idelalisib + 100 mg QD of venetoclax
Trial: NCT02987465
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
Trial: NCT02577523
Drug: ND0612 (Levodopa/Carbidopa solution)
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.